Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG: 3613) announced that it has received the Certificate of Registration of Proprietary Chinese Medicine from the Chinese Medicine Council of Hong Kong (HKCMP), authorizing the sale of Dingzhi Wan【Tong Ren Tang】in the Hong Kong Special Administrative Region – a regulatory milestone that expands the company’s registered proprietary medicine portfolio in one of Asia’s most scrutinized traditional medicine markets.
Regulatory Milestone
| Item | Detail |
|---|---|
| Regulatory Body | Chinese Medicine Council of Hong Kong (HKCMP) |
| Certificate Type | Certificate of Registration of Proprietary Chinese Medicine |
| Product | Dingzhi Wan【Tong Ren Tang】 |
| Registration Number | HKC‑18863 |
| Registrant | Beijing Tong Ren Tang Chinese Medicine Company Limited |
| Registrant Address | 3 Dai King Street, Tai Po Industrial Estate, New Territories, Hong Kong |
| Certificate Validity | Until 29 September 2031 |
| R&D Investment | Approximately HK$800,000 (unaudited, cumulative) |
| Commercial Status | Not yet launched for sale |
Drug Profile & Therapeutic Indications
- Product Type: Proprietary Chinese medicine (registered formulation)
- Core Functions: Supplement qi and nourish the heart; calm and settle the mind
- TCM Indications: Patterns of heart qi instability and deficiency of the five zang organs, manifesting as:
- Worry, grief, and emotional unhappiness
- Restlessness of the heart spirit with a tendency to forgetfulness
- Symptoms exhibiting diurnal variation (mild in the morning, severe in the evening; or recovered in the evening with morning relapse)
- Severe vertigo during acute episodes
- Modern Therapeutic Correlate: The indicated symptom complex overlaps with what modern medicine classifies as mild anxiety, cognitive fatigue, and somatic manifestations of psychological stress – positioning Dingzhi Wan within the growing traditional medicine for mental wellness category
- Formulation Heritage: “Dingzhi Wan” is a classical Chinese medicine formula with centuries of documented use; Tong Ren Tang’s registered version represents a standardized, quality‑controlled proprietary preparation meeting Hong Kong’s regulatory requirements for safety, quality, and labeling
Regulatory Context – Hong Kong Chinese Medicine Framework
| Aspect | Detail |
|---|---|
| Regulatory Authority | Chinese Medicine Council of Hong Kong (HKCMP), established under the Chinese Medicine Ordinance (Cap. 549) |
| Registration Standard | Proprietary Chinese medicines must demonstrate safety, quality, and proper labeling; efficacy claims are evaluated based on traditional use and available evidence |
| Market Significance | Hong Kong’s HKCMP registration is widely regarded as one of the most rigorous traditional medicine regulatory frameworks in Asia, serving as a quality benchmark for Chinese medicine products globally |
| Certificate Duration | 5‑year validity (renewable), requiring ongoing compliance with Good Manufacturing Practice (GMP) and post‑market surveillance |
The HKCMP registration process requires comprehensive documentation of formulation composition, manufacturing processes, quality control standards, and safety data. Obtaining the certificate validates that Dingzhi Wan【Tong Ren Tang】meets Hong Kong’s stringent requirements for proprietary Chinese medicines, providing a quality endorsement that carries weight in both domestic and international traditional medicine markets.
Market Impact & Outlook
- Hong Kong Chinese Medicine Market: Hong Kong serves as a gateway market for premium Chinese medicine products, with annual retail sales of proprietary Chinese medicines estimated in the billions of HKD. The city’s affluent, health‑conscious consumer base and its role as a re‑export hub to Southeast Asia and overseas Chinese communities amplify the commercial significance of HKCMP registration.
- Mental Wellness Opportunity: Dingzhi Wan’s indications – addressing anxiety‑related symptoms, forgetfulness, and stress‑associated vertigo – align with surging consumer demand for traditional medicine alternatives in the mental wellness and cognitive health space, a market segment that has grown significantly post‑pandemic.
- Tong Ren Tang Brand Equity: As one of China’s most recognized and trusted traditional medicine brands with over 350 years of heritage, Tong Ren Tang’s products carry inherent brand premium. The HKCMP registration reinforces the brand’s quality assurance narrative in Hong Kong and international markets.
- Portfolio Expansion: The registration adds a neurological/mental wellness product to Tong Ren Tang’s Hong Kong portfolio, complementing existing cardiovascular, digestive, and immune‑support formulations and broadening the company’s addressable consumer segments.
- Financial Impact: The company stated that the certificate is not expected to have a material impact on production, operations, or financial performance in the near term. Cumulative R&D investment of approximately HK$800,000 reflects a capital‑efficient product registration strategy leveraging established classical formulations.
- Risk Factors: The company noted that pharmaceutical sales in Hong Kong may be influenced by changes in the policy environment, exchange rate fluctuations, and market competition – factors that are standard for Hong Kong‑listed pharmaceutical companies operating in the region.
- Next Steps: Commercial launch timeline, pricing strategy, distribution channels, and marketing plans Not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization, market adoption, and revenue potential of Dingzhi Wan【Tong Ren Tang】in Hong Kong. Receipt of a registration certificate does not guarantee commercial success. Actual outcomes may differ due to risks including market competition, consumer acceptance, regulatory changes, exchange rate movements, and the inherent uncertainties of pharmaceutical product launches.-Fineline Info & Tech
